- Home
- PHAR vs PRSU Comparison
PHAR vs PRSU Comparison
Compare PHAR & PRSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PRSU
- Stock Information
- Founded
- PHAR 1988
- PRSU 1926
- Country
- PHAR Netherlands
- PRSU United States
- Employees
- PHAR N/A
- PRSU N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PRSU Business Services
- Sector
- PHAR Health Care
- PRSU Consumer Discretionary
- Exchange
- PHAR Nasdaq
- PRSU Nasdaq
- Market Cap
- PHAR 718.1M
- PRSU 772.8M
- IPO Year
- PHAR N/A
- PRSU N/A
- Fundamental
- Price
- PHAR $10.45
- PRSU $27.22
- Analyst Decision
- PHAR Strong Buy
- PRSU Strong Buy
- Analyst Count
- PHAR 3
- PRSU 3
- Target Price
- PHAR $30.00
- PRSU $29.67
- AVG Volume (30 Days)
- PHAR 2.6K
- PRSU 263.3K
- Earning Date
- PHAR 07-31-2025
- PRSU 08-15-2025
- Dividend Yield
- PHAR N/A
- PRSU N/A
- EPS Growth
- PHAR N/A
- PRSU N/A
- EPS
- PHAR N/A
- PRSU 11.68
- Revenue
- PHAR $320,708,000.00
- PRSU $366,836,000.00
- Revenue This Year
- PHAR $13.31
- PRSU $13.61
- Revenue Next Year
- PHAR $7.68
- PRSU $6.64
- P/E Ratio
- PHAR N/A
- PRSU $2.33
- Revenue Growth
- PHAR 24.13
- PRSU 189.47
- 52 Week Low
- PHAR $6.65
- PRSU $26.66
- 52 Week High
- PHAR $12.61
- PRSU $47.49
- Technical
- Relative Strength Index (RSI)
- PHAR 47.51
- PRSU N/A
- Support Level
- PHAR $10.41
- PRSU N/A
- Resistance Level
- PHAR $11.50
- PRSU N/A
- Average True Range (ATR)
- PHAR 0.32
- PRSU 0.00
- MACD
- PHAR -0.17
- PRSU 0.00
- Stochastic Oscillator
- PHAR 2.26
- PRSU 0.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PRSU Pursuit Attractions and Hospitality Inc. Common Stock
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.